Global Integrin Alpha 4 Market

Integrin Alpha 4 Comprehensive Study by Application (Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), Melanoma, Celiac Disease, Other:), Type of Therapeutic Agent (TE-5232, ATL-1102, Carotegrast, ET-3764, Natalizumab (Tysabri), Other) Players and Region - Global Market Outlook to 2032

Integrin Alpha 4 Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Integrin Alpha 4
Integrin alpha 4 (α4, alternatively referred to as CD49d) is a transmembrane protein that is a subunit of integrin receptors. It lacks an I-domain and does not go through disulfide-linked cleavage, in contrast to certain other alpha integrin subunits. It pairs with either the beta 1 (β1 or CD29) or beta 7 (β7) subunit to create two different integrin heterodimers: α4β1 (VLA-4) and α4β7 (LPAM-1). These integrins have important functions in cell migration and adhesion through interaction with many ligands. α4β1 interacts with fibronectin and vascular cell adhesion molecule 1 (VCAM-1), facilitating cell-extracellular matrix and cell-cell interactions. It is found on different immune cells, such as lymphocytes, monocytes, and eosinophils, and participates in their migration to areas of inflammation. α4β7 interacts with fibronectin and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and is mainly responsible for directing lymphocyte homing to the gut-associated lymphoid tissue. Because of their role in immune cell trafficking in inflammatory conditions, α4 integrins, especially α4β1, are important therapeutic targets, and natalizumab is an example of an α4-blocking antibody that has been used in the treatment of multiple sclerosis and Crohn's disease.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche AG (Basel, Switzerland), Pfizer Inc. (New York City, New York, USA), AbbVie Inc. (North Chicago, Illinois, USA), Eli Lilly and Company (Indianapolis, Indiana, USA), Merck & Co., Inc. (Rahway, New Jersey, USA), Bristol Myers Squibb (New York City, New York, USA), AstraZeneca PLC (Cambridge, United Kingdom), Sanofi S.A. (Paris, France), Gilead Sciences, Inc. (Foster City, California, USA) and Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Integrin Alpha 4 market by , Application (Multiple Sclerosis (MS), Inflammatory Bowel Disease (IBD), Melanoma, Celiac Disease and Other:) and Region.



On the basis of geography, the market of Integrin Alpha 4 has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Type of Therapeutic Agent, the sub-segment i.e. TE-5232 will boost the Integrin Alpha 4 market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.



About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Multiple Sclerosis (MS)
  • Inflammatory Bowel Disease (IBD)
  • Melanoma
  • Celiac Disease
  • Other:
By Type of Therapeutic Agent
  • TE-5232
  • ATL-1102
  • Carotegrast
  • ET-3764
  • Natalizumab (Tysabri)
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global Integrin Alpha 4, by Application, Type of Therapeutic Agent and Region (value) (2019-2024)
    • 4.1. Introduction
    • 4.2. Global Integrin Alpha 4 (Value)
      • 4.2.1. Global Integrin Alpha 4 by: Application (Value)
        • 4.2.1.1. Multiple Sclerosis (MS)
        • 4.2.1.2. Inflammatory Bowel Disease (IBD)
        • 4.2.1.3. Melanoma
        • 4.2.1.4. Celiac Disease
        • 4.2.1.5. Other:
      • 4.2.2. Global Integrin Alpha 4 by: Type of Therapeutic Agent (Value)
        • 4.2.2.1. TE-5232
        • 4.2.2.2. ATL-1102
        • 4.2.2.3. Carotegrast
        • 4.2.2.4. ET-3764
        • 4.2.2.5. Natalizumab (Tysabri)
        • 4.2.2.6. Other
      • 4.2.3. Global Integrin Alpha 4 Region
        • 4.2.3.1. South America
          • 4.2.3.1.1. Brazil
          • 4.2.3.1.2. Argentina
          • 4.2.3.1.3. Rest of South America
        • 4.2.3.2. Asia Pacific
          • 4.2.3.2.1. China
          • 4.2.3.2.2. Japan
          • 4.2.3.2.3. India
          • 4.2.3.2.4. South Korea
          • 4.2.3.2.5. Taiwan
          • 4.2.3.2.6. Australia
          • 4.2.3.2.7. Rest of Asia-Pacific
        • 4.2.3.3. Europe
          • 4.2.3.3.1. Germany
          • 4.2.3.3.2. France
          • 4.2.3.3.3. Italy
          • 4.2.3.3.4. United Kingdom
          • 4.2.3.3.5. Netherlands
          • 4.2.3.3.6. Rest of Europe
        • 4.2.3.4. MEA
          • 4.2.3.4.1. Middle East
          • 4.2.3.4.2. Africa
        • 4.2.3.5. North America
          • 4.2.3.5.1. United States
          • 4.2.3.5.2. Canada
          • 4.2.3.5.3. Mexico
  • 5. Integrin Alpha 4: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2024)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. F. Hoffmann-La Roche AG (Basel, Switzerland)
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. Pfizer Inc. (New York City, New York, USA)
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. AbbVie Inc. (North Chicago, Illinois, USA)
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. Eli Lilly and Company (Indianapolis, Indiana, USA)
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. Merck & Co., Inc. (Rahway, New Jersey, USA)
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. Bristol Myers Squibb (New York City, New York, USA)
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. AstraZeneca PLC (Cambridge, United Kingdom)
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. Sanofi S.A. (Paris, France)
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Gilead Sciences, Inc. (Foster City, California, USA)
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA)
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
  • 6. Global Integrin Alpha 4 Sale, by Application, Type of Therapeutic Agent and Region (value) (2027-2032)
    • 6.1. Introduction
    • 6.2. Global Integrin Alpha 4 (Value)
      • 6.2.1. Global Integrin Alpha 4 by: Application (Value)
        • 6.2.1.1. Multiple Sclerosis (MS)
        • 6.2.1.2. Inflammatory Bowel Disease (IBD)
        • 6.2.1.3. Melanoma
        • 6.2.1.4. Celiac Disease
        • 6.2.1.5. Other:
      • 6.2.2. Global Integrin Alpha 4 by: Type of Therapeutic Agent (Value)
        • 6.2.2.1. TE-5232
        • 6.2.2.2. ATL-1102
        • 6.2.2.3. Carotegrast
        • 6.2.2.4. ET-3764
        • 6.2.2.5. Natalizumab (Tysabri)
        • 6.2.2.6. Other
      • 6.2.3. Global Integrin Alpha 4 Region
        • 6.2.3.1. South America
          • 6.2.3.1.1. Brazil
          • 6.2.3.1.2. Argentina
          • 6.2.3.1.3. Rest of South America
        • 6.2.3.2. Asia Pacific
          • 6.2.3.2.1. China
          • 6.2.3.2.2. Japan
          • 6.2.3.2.3. India
          • 6.2.3.2.4. South Korea
          • 6.2.3.2.5. Taiwan
          • 6.2.3.2.6. Australia
          • 6.2.3.2.7. Rest of Asia-Pacific
        • 6.2.3.3. Europe
          • 6.2.3.3.1. Germany
          • 6.2.3.3.2. France
          • 6.2.3.3.3. Italy
          • 6.2.3.3.4. United Kingdom
          • 6.2.3.3.5. Netherlands
          • 6.2.3.3.6. Rest of Europe
        • 6.2.3.4. MEA
          • 6.2.3.4.1. Middle East
          • 6.2.3.4.2. Africa
        • 6.2.3.5. North America
          • 6.2.3.5.1. United States
          • 6.2.3.5.2. Canada
          • 6.2.3.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. Integrin Alpha 4: by Application(USD Million)
  • Table 2. Integrin Alpha 4 Multiple Sclerosis (MS) , by Region USD Million (2019-2024)
  • Table 3. Integrin Alpha 4 Inflammatory Bowel Disease (IBD) , by Region USD Million (2019-2024)
  • Table 4. Integrin Alpha 4 Melanoma , by Region USD Million (2019-2024)
  • Table 5. Integrin Alpha 4 Celiac Disease , by Region USD Million (2019-2024)
  • Table 6. Integrin Alpha 4 Other: , by Region USD Million (2019-2024)
  • Table 7. Integrin Alpha 4: by Type of Therapeutic Agent(USD Million)
  • Table 8. Integrin Alpha 4 TE-5232 , by Region USD Million (2019-2024)
  • Table 9. Integrin Alpha 4 ATL-1102 , by Region USD Million (2019-2024)
  • Table 10. Integrin Alpha 4 Carotegrast , by Region USD Million (2019-2024)
  • Table 11. Integrin Alpha 4 ET-3764 , by Region USD Million (2019-2024)
  • Table 12. Integrin Alpha 4 Natalizumab (Tysabri) , by Region USD Million (2019-2024)
  • Table 13. Integrin Alpha 4 Other , by Region USD Million (2019-2024)
  • Table 14. South America Integrin Alpha 4, by Country USD Million (2019-2024)
  • Table 15. South America Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 16. South America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 17. Brazil Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 18. Brazil Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 19. Argentina Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 20. Argentina Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 21. Rest of South America Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 22. Rest of South America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 23. Asia Pacific Integrin Alpha 4, by Country USD Million (2019-2024)
  • Table 24. Asia Pacific Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 25. Asia Pacific Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 26. China Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 27. China Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 28. Japan Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 29. Japan Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 30. India Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 31. India Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 32. South Korea Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 33. South Korea Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 34. Taiwan Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 35. Taiwan Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 36. Australia Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 37. Australia Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 38. Rest of Asia-Pacific Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 39. Rest of Asia-Pacific Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 40. Europe Integrin Alpha 4, by Country USD Million (2019-2024)
  • Table 41. Europe Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 42. Europe Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 43. Germany Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 44. Germany Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 45. France Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 46. France Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 47. Italy Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 48. Italy Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 49. United Kingdom Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 50. United Kingdom Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 51. Netherlands Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 52. Netherlands Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 53. Rest of Europe Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 54. Rest of Europe Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 55. MEA Integrin Alpha 4, by Country USD Million (2019-2024)
  • Table 56. MEA Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 57. MEA Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 58. Middle East Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 59. Middle East Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 60. Africa Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 61. Africa Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 62. North America Integrin Alpha 4, by Country USD Million (2019-2024)
  • Table 63. North America Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 64. North America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 65. United States Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 66. United States Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 67. Canada Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 68. Canada Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 69. Mexico Integrin Alpha 4, by Application USD Million (2019-2024)
  • Table 70. Mexico Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2019-2024)
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Integrin Alpha 4: by Application(USD Million)
  • Table 82. Integrin Alpha 4 Multiple Sclerosis (MS) , by Region USD Million (2027-2032)
  • Table 83. Integrin Alpha 4 Inflammatory Bowel Disease (IBD) , by Region USD Million (2027-2032)
  • Table 84. Integrin Alpha 4 Melanoma , by Region USD Million (2027-2032)
  • Table 85. Integrin Alpha 4 Celiac Disease , by Region USD Million (2027-2032)
  • Table 86. Integrin Alpha 4 Other: , by Region USD Million (2027-2032)
  • Table 87. Integrin Alpha 4: by Type of Therapeutic Agent(USD Million)
  • Table 88. Integrin Alpha 4 TE-5232 , by Region USD Million (2027-2032)
  • Table 89. Integrin Alpha 4 ATL-1102 , by Region USD Million (2027-2032)
  • Table 90. Integrin Alpha 4 Carotegrast , by Region USD Million (2027-2032)
  • Table 91. Integrin Alpha 4 ET-3764 , by Region USD Million (2027-2032)
  • Table 92. Integrin Alpha 4 Natalizumab (Tysabri) , by Region USD Million (2027-2032)
  • Table 93. Integrin Alpha 4 Other , by Region USD Million (2027-2032)
  • Table 94. South America Integrin Alpha 4, by Country USD Million (2027-2032)
  • Table 95. South America Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 96. South America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 97. Brazil Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 98. Brazil Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 99. Argentina Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 100. Argentina Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 101. Rest of South America Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 102. Rest of South America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 103. Asia Pacific Integrin Alpha 4, by Country USD Million (2027-2032)
  • Table 104. Asia Pacific Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 105. Asia Pacific Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 106. China Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 107. China Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 108. Japan Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 109. Japan Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 110. India Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 111. India Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 112. South Korea Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 113. South Korea Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 114. Taiwan Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 115. Taiwan Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 116. Australia Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 117. Australia Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 118. Rest of Asia-Pacific Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 119. Rest of Asia-Pacific Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 120. Europe Integrin Alpha 4, by Country USD Million (2027-2032)
  • Table 121. Europe Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 122. Europe Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 123. Germany Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 124. Germany Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 125. France Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 126. France Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 127. Italy Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 128. Italy Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 129. United Kingdom Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 130. United Kingdom Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 131. Netherlands Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 132. Netherlands Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 133. Rest of Europe Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 134. Rest of Europe Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 135. MEA Integrin Alpha 4, by Country USD Million (2027-2032)
  • Table 136. MEA Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 137. MEA Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 138. Middle East Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 139. Middle East Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 140. Africa Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 141. Africa Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 142. North America Integrin Alpha 4, by Country USD Million (2027-2032)
  • Table 143. North America Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 144. North America Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 145. United States Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 146. United States Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 147. Canada Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 148. Canada Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 149. Mexico Integrin Alpha 4, by Application USD Million (2027-2032)
  • Table 150. Mexico Integrin Alpha 4, by Type of Therapeutic Agent USD Million (2027-2032)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Integrin Alpha 4: by Application USD Million (2019-2024)
  • Figure 5. Global Integrin Alpha 4: by Type of Therapeutic Agent USD Million (2019-2024)
  • Figure 6. South America Integrin Alpha 4 Share (%), by Country
  • Figure 7. Asia Pacific Integrin Alpha 4 Share (%), by Country
  • Figure 8. Europe Integrin Alpha 4 Share (%), by Country
  • Figure 9. MEA Integrin Alpha 4 Share (%), by Country
  • Figure 10. North America Integrin Alpha 4 Share (%), by Country
  • Figure 11. Global Integrin Alpha 4 share by Players 2024 (%)
  • Figure 12. Global Integrin Alpha 4 share by Players (Top 3) 2024(%)
  • Figure 13. Global Integrin Alpha 4 share by Players (Top 5) 2024(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. F. Hoffmann-La Roche AG (Basel, Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. F. Hoffmann-La Roche AG (Basel, Switzerland) Revenue: by Geography 2024
  • Figure 17. Pfizer Inc. (New York City, New York, USA) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (New York City, New York, USA) Revenue: by Geography 2024
  • Figure 19. AbbVie Inc. (North Chicago, Illinois, USA) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie Inc. (North Chicago, Illinois, USA) Revenue: by Geography 2024
  • Figure 21. Eli Lilly and Company (Indianapolis, Indiana, USA) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly and Company (Indianapolis, Indiana, USA) Revenue: by Geography 2024
  • Figure 23. Merck & Co., Inc. (Rahway, New Jersey, USA) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (Rahway, New Jersey, USA) Revenue: by Geography 2024
  • Figure 25. Bristol Myers Squibb (New York City, New York, USA) Revenue, Net Income and Gross profit
  • Figure 26. Bristol Myers Squibb (New York City, New York, USA) Revenue: by Geography 2024
  • Figure 27. AstraZeneca PLC (Cambridge, United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. AstraZeneca PLC (Cambridge, United Kingdom) Revenue: by Geography 2024
  • Figure 29. Sanofi S.A. (Paris, France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A. (Paris, France) Revenue: by Geography 2024
  • Figure 31. Gilead Sciences, Inc. (Foster City, California, USA) Revenue, Net Income and Gross profit
  • Figure 32. Gilead Sciences, Inc. (Foster City, California, USA) Revenue: by Geography 2024
  • Figure 33. Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA) Revenue, Net Income and Gross profit
  • Figure 34. Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA) Revenue: by Geography 2024
  • Figure 35. Global Integrin Alpha 4: by Application USD Million (2027-2032)
  • Figure 36. Global Integrin Alpha 4: by Type of Therapeutic Agent USD Million (2027-2032)
  • Figure 37. South America Integrin Alpha 4 Share (%), by Country
  • Figure 38. Asia Pacific Integrin Alpha 4 Share (%), by Country
  • Figure 39. Europe Integrin Alpha 4 Share (%), by Country
  • Figure 40. MEA Integrin Alpha 4 Share (%), by Country
  • Figure 41. North America Integrin Alpha 4 Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche AG (Basel, Switzerland)
  • Pfizer Inc. (New York City, New York, USA)
  • AbbVie Inc. (North Chicago, Illinois, USA)
  • Eli Lilly and Company (Indianapolis, Indiana, USA)
  • Merck & Co., Inc. (Rahway, New Jersey, USA)
  • Bristol Myers Squibb (New York City, New York, USA)
  • AstraZeneca PLC (Cambridge, United Kingdom)
  • Sanofi S.A. (Paris, France)
  • Gilead Sciences, Inc. (Foster City, California, USA)
  • Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA)
Select User Access Type

Key Highlights of Report


Apr 2025 213 Pages 57 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Integrin Alpha 4 Market Quantitative research analysis
Global Integrin Alpha 4 Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche AG (Basel, Switzerland), Pfizer Inc. (New York City, New York, USA), AbbVie Inc. (North Chicago, Illinois, USA), Eli Lilly and Company (Indianapolis, Indiana, USA), Merck & Co., Inc. (Rahway, New Jersey, USA), Bristol Myers Squibb (New York City, New York, USA), AstraZeneca PLC (Cambridge, United Kingdom), Sanofi S.A. (Paris, France), Gilead Sciences, Inc. (Foster City, California, USA) and Vertex Pharmaceuticals Incorporated (Boston, Massachusetts, USA) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Integrin Alpha 4 Market during projected period 2024-2032.
The Integrin Alpha 4 market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Integrin Alpha 4 Market Report?

Have a Query? Click Here

Other Related Reports

Digital Video Sales Comprehensive Study by Application (Retail, IT and Telecom, Media and Entertainment, Automotive, Financial Services, Consumer Goods and Electronics, Others), Type (Desktop, Mobile...
$ 3800
nanobots/nanorobots Comprehensive Study by Application (NanoMedicine, Biomedical, Others), Product Type (Nanomanipulator, Bio-Nanorobotics, Magnetically Guided Nanobots/Nanorobots, Others) Players an...
$ 3800
Tunnel Seismic Prediction (TSP) Technology Comprehensive Study by Application (Railway Engineering, Highway Engineering, Water Conservancy and Hydropower Engineering, Mining Engineering, Other), Type...
$ 3800
Screenless Display Technology Future-proof Comprehensive Study by Application (Holographic Projection, Head-mounted Display, Head-up Display, Others), Type (Visual Image, Retinal Display, Synaptic I...
$ 3800
In-Vitro Diagnostics Technology Comprehensive Study by Application (Diabetes, Infectious Diseases, Oncology, Cardiology, Autoimmune Diseases, Nephrology, Drug Testing/Pharmacogenomics, HIV/Aids, Othe...
$ 3800
Virtual Concierge Services Comprehensive Study by Delivery Model (In-Person Services, Virtual Concierge Services), End-Use Industry (Hospitality, Corporate Sector, Healthcare, Luxury Real Estate), Se...
$ 3800